NTX 1107
Alternative Names: NTX-1107Latest Information Update: 30 Sep 2026
At a glance
- Originator Nectin Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Nectin modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 30 Sep 2026 NTX 1107 is still in preclinical development in Haematological-malignancies in USA (Parenteral) (Nectin Therapeutics pipeline, September 2026)
- 30 Sep 2026 NTX 1107 is still in preclinical development in Solid-tumours in USA (Parenteral) (Nectin Therapeutics pipeline, September 2026)
- 28 Apr 2026 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)